JP4651816B2 - クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物 - Google Patents

クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物 Download PDF

Info

Publication number
JP4651816B2
JP4651816B2 JP2000557825A JP2000557825A JP4651816B2 JP 4651816 B2 JP4651816 B2 JP 4651816B2 JP 2000557825 A JP2000557825 A JP 2000557825A JP 2000557825 A JP2000557825 A JP 2000557825A JP 4651816 B2 JP4651816 B2 JP 4651816B2
Authority
JP
Japan
Prior art keywords
disease
use according
doxycycline
tetracycline
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2000557825A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002519374A5 (enExample
JP2002519374A (ja
Inventor
カール ウィリアム バウムガート
トーマス ジュリアス ボロディー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2002519374A publication Critical patent/JP2002519374A/ja
Publication of JP2002519374A5 publication Critical patent/JP2002519374A5/ja
Application granted granted Critical
Publication of JP4651816B2 publication Critical patent/JP4651816B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2000557825A 1998-06-30 1999-06-30 クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物 Expired - Lifetime JP4651816B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP4376A AUPP437698A0 (en) 1998-06-30 1998-06-30 Methods for treatment of coronary, carotid and other vascular disease
AU4376 1998-06-30
PCT/AU1999/000528 WO2000001378A1 (en) 1998-06-30 1999-06-30 Methods and compositions for treatment of disorders associated with chlamydial and similar bacterial infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010074109A Division JP5335726B2 (ja) 1998-06-30 2010-03-29 クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物

Publications (3)

Publication Number Publication Date
JP2002519374A JP2002519374A (ja) 2002-07-02
JP2002519374A5 JP2002519374A5 (enExample) 2006-07-13
JP4651816B2 true JP4651816B2 (ja) 2011-03-16

Family

ID=3808619

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2000557825A Expired - Lifetime JP4651816B2 (ja) 1998-06-30 1999-06-30 クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物
JP2010074109A Expired - Lifetime JP5335726B2 (ja) 1998-06-30 2010-03-29 クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物
JP2013076511A Pending JP2013147504A (ja) 1998-06-30 2013-04-02 クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2010074109A Expired - Lifetime JP5335726B2 (ja) 1998-06-30 2010-03-29 クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物
JP2013076511A Pending JP2013147504A (ja) 1998-06-30 2013-04-02 クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物

Country Status (10)

Country Link
US (1) US6475518B1 (enExample)
EP (2) EP1093363B1 (enExample)
JP (3) JP4651816B2 (enExample)
AT (1) ATE345115T1 (enExample)
AU (2) AUPP437698A0 (enExample)
CA (2) CA2684402C (enExample)
DE (1) DE69934010T2 (enExample)
ES (2) ES2278449T3 (enExample)
NZ (1) NZ509504A (enExample)
WO (1) WO2000001378A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710033B1 (en) 1996-08-14 2004-03-23 Vanderbilt University Methods and treatment of multiple sclerosis
US6258532B1 (en) 1997-08-14 2001-07-10 Vanderbilt University Methods for in vitro susceptibility testing of chlamydia
US6756369B2 (en) * 1997-05-06 2004-06-29 Vanderbilt University Diagnosis and management of infection caused by Chlamydia
US6890526B2 (en) 1997-05-06 2005-05-10 Vanderbilt University Methods and reagents for the treatment of multiple sclerosis
EP1166117A2 (en) * 1999-03-19 2002-01-02 Vanderbilt University Diagnosis and treatment of multiple sclerosis
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
AU3984101A (en) * 2000-02-24 2001-09-03 Advanced Pharma Inc Antibiotic and antifungal compositions
UA77654C2 (en) * 2000-03-22 2007-01-15 Upjohn Co Compressed tablet of linezolide
US6514529B2 (en) 2000-03-22 2003-02-04 Pharmacia & Upjohn Company Oxazolidinone tablet formulation
IT1318459B1 (it) 2000-04-11 2003-08-25 Zambon Spa Uso del tiamfenicolo e di suoi derivati per la preparazione dicomposizioni farmaceutiche utili per il trattamento di infezioni da
US20020169112A1 (en) * 2001-05-08 2002-11-14 Luc Montagnier Combined treatments and methods for treatment of mycoplasma and mycoplasma-like organism infections
EP1262185A1 (en) * 2001-05-30 2002-12-04 New Pharma Research Sweden AB Synergistic antibiotic compositions
WO2003004098A1 (en) * 2001-07-06 2003-01-16 Sucampo Ag Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
UA79952C2 (en) * 2001-12-10 2007-08-10 Kabulesh Mafatlal Khamar MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT
AUPS017702A0 (en) * 2002-01-25 2002-02-14 Atopic Pty Ltd Methods and compositions for the treatment of asthma and related disorders
AUPS088702A0 (en) * 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
WO2003075852A2 (en) * 2002-03-07 2003-09-18 Advancis Pharmaceuticals Corporation Antibiotic composition
US20040077533A1 (en) * 2002-05-23 2004-04-22 Sayada Chalom B. Methods and compositions for treating bacterial infections and diseases associated therewith
AU2003265241A1 (en) * 2002-05-23 2003-12-12 Activbiotics, Inc. Methods of treating bacterial infections and diseases associated therewith
US20090149453A1 (en) * 2002-05-23 2009-06-11 Activbiotics Pharma Llc Methods and compositions for treating bacterial infections and diseases associated therewith
US6916627B2 (en) * 2002-11-27 2005-07-12 St. Jude Children's Research Hospital ATM kinase compositions and methods
US7108992B2 (en) * 2002-11-27 2006-09-19 St. Jude Children's Research Hospital ATM kinase compositions and methods
WO2004054548A1 (en) * 2002-12-12 2004-07-01 Activbiotics,Inc. Method and reagents for treating or preventing atherosclerosis and diseases associated therewith
WO2004054513A2 (en) * 2002-12-12 2004-07-01 Activbiotics, Inc. Methods and compositions for treating and preventing ear infections
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
RU2254123C2 (ru) * 2003-08-11 2005-06-20 Государственное научное учреждение Институт экспериментальной ветеринарии Сибири и Дальнего Востока Сибирского отделения Россельхозакадемии (ГНУ ИЭВСиДВ СО РАСХН) Препарат для лечения гемобартонеллеза кошек и способ его применения
WO2005027961A2 (en) * 2003-09-23 2005-03-31 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Chlamydia pmpd autotransporter and its role as adhesin
NZ549661A (en) 2004-02-06 2010-07-30 Pharmatel R & D Pty Ltd As Tru Use of aminosalicylates in diarrhoea-predominant irritable bowel syndrome
JP5009152B2 (ja) * 2004-05-28 2012-08-22 サリックス ファーマシューティカルズ， インコーポレイテッド 放射線誘発性腸炎の予防、処置、および回復
JP5047797B2 (ja) 2004-09-30 2012-10-10 コヴァロン・テクノロジーズ・インコーポレーテッド 非接着性の弾性ゼラチンマトリックス
JPWO2006057429A1 (ja) * 2004-11-24 2008-06-05 ナノキャリア株式会社 ブロックコポリマーのモーフォロジーの変化方法
US7452872B2 (en) * 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CN101247812A (zh) * 2005-08-24 2008-08-20 萨利克斯药品公司 巴柳氮制剂及其生产和应用
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
FR2891744B1 (fr) * 2005-10-06 2009-10-09 France Etat Armement Application a la chimioprophylaxie du paludisme d'une association de chloroquine et de doxycycline
US8647673B2 (en) * 2007-07-24 2014-02-11 Wayne State University Nanoparticles for imaging and treating chlamydial infection
ES2645692T3 (es) 2008-11-11 2017-12-07 The Board Of Regents,The University Of Texas System Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
GB2548296A (en) * 2009-10-22 2017-09-13 Borody Thomas J Novel parasite therapy
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US8497256B2 (en) 2010-04-26 2013-07-30 Salix Pharmaceuticals, Ltd Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males
NZ611868A (en) 2010-12-13 2015-11-27 Salix Pharmaceuticals Inc Gastric and colonic formulations and methods for making and using them
CN103813977A (zh) * 2011-08-16 2014-05-21 普拉克生化公司 可用于发酵液处理的通过用盐酸沉淀从羧酸镁盐中回收羧酸的方法
EP2877163B1 (en) 2012-07-27 2019-03-20 Redhill Biopharma Ltd. Formulations and methods of manufacturing formulations for use in colonic evacuation
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
MX382754B (es) * 2015-10-06 2025-03-13 Redhill Biopharma Ltd Terapias combinadas para tratar el cancer.
US11197872B2 (en) 2017-04-21 2021-12-14 Lunella Biotech, Inc. Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs)
WO2018195446A1 (en) 2017-04-21 2018-10-25 Lisanti Michael P Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy
EP3624840A4 (en) 2017-05-19 2021-03-10 Lunella Biotech, Inc. ANTIMITOSCINE: TARGETED INHIBITORS OF MITOCHONDRIAL BIOGENESIS TO DESCRIBE CANCER STEM CELLS
US12006553B2 (en) 2017-05-19 2024-06-11 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
EP3644988B1 (en) 2017-06-26 2023-02-22 Lunella Biotech, Inc. Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells
CN111757732A (zh) * 2018-02-01 2020-10-09 消化系统疾病中心 用于治疗感染性动脉疾病和相关病状的组合物
RU2684728C1 (ru) * 2018-05-21 2019-04-12 федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный аграрный университет" Препарат на основе пчелиного маточного молочка для лечения мелких домашних животных при гемобартонеллезе
WO2021191456A1 (en) * 2020-03-27 2021-09-30 Vectura Limited Compositions for the treatment of a respiratory condition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US588550A (en) 1897-08-24 Alarm-clock
GB1463550A (en) 1974-08-06 1977-02-02 Bodrero G Pharmaceutical composition
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
FI883067A7 (fi) * 1988-06-27 1989-12-28 Labsystems Oy Foerfarande foer behandling av koronarkaerlsjukdom.
US5914132A (en) 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
GB9416600D0 (en) 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
US5624704A (en) 1995-04-24 1997-04-29 Baylor College Of Medicine Antimicrobial impregnated catheters and other medical implants and method for impregnating catheters and other medical implants with an antimicrobial agent
US6080757A (en) * 1996-06-06 2000-06-27 Pfizer Inc Antibiotic quinolones and derivatives
US6838552B1 (en) * 1997-08-14 2005-01-04 Vanderbilt University Diagnosis and management of infection caused by Chlamydia
US5811121A (en) 1997-01-29 1998-09-22 Eastman Chemical Company PH-sensitive coatings based on cellulose acetoacetate
JP2002512622A (ja) * 1997-05-06 2002-04-23 バンダービルト ユニバーシティー クラミジアにより引き起こされる感染の診断および管理のための抗クラミジア剤の組成物

Also Published As

Publication number Publication date
NZ509504A (en) 2004-04-30
EP1093363B1 (en) 2006-11-15
DE69934010D1 (de) 2006-12-28
WO2000001378A1 (en) 2000-01-13
EP1093363A4 (en) 2003-09-24
ES2278449T3 (es) 2007-08-01
JP2010174030A (ja) 2010-08-12
EP1093363A1 (en) 2001-04-25
ATE345115T1 (de) 2006-12-15
CA2336593A1 (en) 2000-01-13
JP2013147504A (ja) 2013-08-01
DE69934010T2 (de) 2007-06-21
CA2336593C (en) 2010-06-29
AU757293B2 (en) 2003-02-13
EP1754472A3 (en) 2009-08-26
US6475518B1 (en) 2002-11-05
ES2514469T3 (es) 2014-10-28
AUPP437698A0 (en) 1998-07-23
HK1037864A1 (en) 2002-02-22
JP5335726B2 (ja) 2013-11-06
EP1754472A2 (en) 2007-02-21
EP1754472B1 (en) 2014-07-23
CA2684402A1 (en) 2000-01-13
CA2684402C (en) 2012-10-30
AU4591999A (en) 2000-01-24
JP2002519374A (ja) 2002-07-02

Similar Documents

Publication Publication Date Title
JP4651816B2 (ja) クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物
EP1811979B1 (en) Microcapsules comprising a methylxanthine and a corticosteroid
AU718971C (en) Colonic delivery of nicotine to treat inflammatory bowel disease
US11723874B2 (en) Delayed release deferiprone tablets and methods of using the same
WO2001078681A1 (en) Drug delivery system for avoiding pharmacokinetic interaction between drugs and method thereof
KR100581967B1 (ko) 소화성 궤양 치료를 위한 프로톤펌프 저해제와클래리스로마이신을 함유하는 이중 펠렛 제제 및 그의제조방법
JP2025522785A (ja) 多発性硬化症及び重症筋無力症に対する治療用チロシンキナーゼ阻害剤
HK1037864B (en) Compositions for treatment of disorders associated with chlamydia
RU2498803C1 (ru) Противотуберкулезное лекарственное средство
RU123325U1 (ru) Гранула противотуберкулезного лекарственного средства
EA042135B1 (ru) Таблетка деферипрона с отсроченным высвобождением и способ ее изготовления

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060512

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080229

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100318

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100421

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100720

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101015

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101125

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101215

R150 Certificate of patent or registration of utility model

Ref document number: 4651816

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131224

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term